A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients’ risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during t…
Tag Archives | san antonio breast cancer symposium
Simple fingertip test may identify breast cancer patients at risk for carpal tunnel syndrome
A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients’ risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during t…
Combination therapy reduced HER2-positive breast cancers
SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR Sa…
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual …
Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results…
Tamoxifen-Resistant Breast Cancers Become Receptive to New Therapies
Breast cancer tumors that stop responding to the drug tamoxifen actually change their cellular characteristics and become responsive to other types of drugs, including Herceptin, according to oncologists at the Duke Comprehensive Cancer Center. “In the process of becoming resistant to tamoxifen, the tumors alter their qualities and become receptive to Herceptin and other drugs that target the HER-2 receptor,” said Kimberly Blackwell, M.D., assistant professor of oncology at Duke.
‘Dose Dense’ Chemo Improves Survival in Breast Cancer Patients
A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. While previous research has evaluated the use of various forms of “dose dense” chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer.